{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:25:40Z","timestamp":1795119940695,"version":"4.10.3"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-1-0084"],"award-info":[{"award-number":["W81XWH-17-1-0084"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"G.G. is partly supported by the Paul C. Zamecnik Chair in Oncology at the Massachusetts General Hospital Cancer Center.","id":[{"id":"https:\/\/ror.org\/002pd6e78","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-17-1-0084"],"award-info":[{"award-number":["W81XWH-17-1-0084"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA240243"],"award-info":[{"award-number":["P50CA240243"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5K08CA191058-05"],"award-info":[{"award-number":["5K08CA191058-05"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mutagenic processes and clonal selection contribute to the development of therapy-associated secondary neoplasms, a known complication of cancer treatment. The association between tamoxifen therapy and secondary uterine cancers is uncommon but well established; however, the genetic mechanisms underlying tamoxifen-driven tumorigenesis remain unclear. We find that oncogenic\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    mutations, common in spontaneously arising estrogen-associated de novo uterine cancer, are significantly less frequent in tamoxifen-associated tumors. In vivo, tamoxifen-induced estrogen receptor stimulation activates phosphoinositide 3-kinase (PI3K) signaling in normal mouse uterine tissue, potentially eliminating the selective benefit of PI3K-activating mutations in tamoxifen-associated uterine cancer. Together, we present a unique pathway of therapy-associated carcinogenesis in which tamoxifen-induced activation of the PI3K pathway acts as a non-genetic driver event, contributing to the multistep model of uterine carcinogenesis. While this PI3K mechanism is specific to tamoxifen-associated uterine cancer, the concept of treatment-induced signaling events may have broader applicability to other routes of tumorigenesis.\n                  <\/jats:p>","DOI":"10.1038\/s41588-025-02308-w","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T09:03:26Z","timestamp":1755853406000},"page":"2192-2202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Tamoxifen induces PI3K activation in uterine cancer"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-5579","authenticated-orcid":false,"given":"Kirsten","family":"K\u00fcbler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankara","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gurevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5739-1781","authenticated-orcid":false,"given":"Jianjiong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Droog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2916-0337","authenticated-orcid":false,"given":"Francisco","family":"Hermida-Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Akhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Feiglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery S.","family":"Feit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Cohen Feit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen","family":"Dackus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Pun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6026-2211","authenticated-orcid":false,"given":"Justin","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendy","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9209-5403","authenticated-orcid":false,"given":"Sebastian","family":"Gregoricchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirthe","family":"Lanfermeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2287-5663","authenticated-orcid":false,"given":"Cloud P.","family":"Paweletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4444","authenticated-orcid":false,"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora E.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2358-9765","authenticated-orcid":false,"given":"Petra M.","family":"Nederlof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quang-D\u00e9","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian J. E.","family":"Mourits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Radovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignaty","family":"Leshchiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chip","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9823-7289","authenticated-orcid":false,"given":"Wilbert","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef E.","family":"Maruvka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-7529","authenticated-orcid":false,"given":"Rinath","family":"Jeselsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"2308_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33663-5","volume":"13","author":"E Kuijk","year":"2022","unstructured":"Kuijk, E., Kranenburg, O., Cuppen, E. & Van Hoeck, A. Common anti-cancer therapies induce somatic mutations in stem cells of healthy tissue. Nat. Commun. 13, 5915 (2022).","journal-title":"Nat. Commun."},{"key":"2308_CR2","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/carcin\/16.6.1299","volume":"16","author":"P Carthew","year":"1995","unstructured":"Carthew, P. et al. DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis 16, 1299\u20131304 (1995).","journal-title":"Carcinogenesis"},{"key":"2308_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s002040100244","volume":"75","author":"P Carthew","year":"2001","unstructured":"Carthew, P. et al. Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat. Arch. Toxicol. 75, 375\u2013380 (2001).","journal-title":"Arch. Toxicol."},{"key":"2308_CR4","first-page":"S1-98","volume":"24","author":"H Busch","year":"1997","unstructured":"Busch, H. Adducts and tamoxifen. Semin. Oncol. 24, S1-98\u2013S1-104 (1997).","journal-title":"Semin. Oncol."},{"key":"2308_CR5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/carcin\/bgu029","volume":"35","author":"EE Hernandez-Ramon","year":"2014","unstructured":"Hernandez-Ramon, E. E. et al. Tamoxifen\u2013DNA adduct formation in monkey and human reproductive organs. Carcinogenesis 35, 1172\u20131176 (2014).","journal-title":"Carcinogenesis"},{"key":"2308_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1124\/dmd.109.029488","volume":"38","author":"H Andersson","year":"2010","unstructured":"Andersson, H., Helmestam, M., Zebrowska, A., Olovsson, M. & Brittebo, E. Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab. Dispos. 38, 200\u2013207 (2010).","journal-title":"Drug Metab. Dispos."},{"key":"2308_CR7","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1021\/tx050019l","volume":"18","author":"SY Kim","year":"2005","unstructured":"Kim, S. Y. et al. Formation of tamoxifen\u2013DNA adducts in human endometrial explants exposed to \u03b1-hydroxytamoxifen. Chem. Res. Toxicol. 18, 889\u2013895 (2005).","journal-title":"Chem. Res. Toxicol."},{"key":"2308_CR8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/bjc.1971.33","volume":"25","author":"MP Cole","year":"1971","unstructured":"Cole, M. P., Jones, C. T. & Todd, I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br. J. Cancer 25, 270\u2013275 (1971).","journal-title":"Br. J. Cancer"},{"key":"2308_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1200\/JCO.1986.4.4.459","volume":"4","author":"B Fisher","year":"1986","unstructured":"Fisher, B. et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J. Clin. Oncol. 4, 459\u2013471 (1986).","journal-title":"J. Clin. Oncol."},{"key":"2308_CR10","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90, 1371\u20131388 (1998).","journal-title":"J. Natl Cancer Inst."},{"key":"2308_CR11","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group.","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386, 1341\u20131352 (2015).","journal-title":"Lancet"},{"key":"2308_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379, 111\u2013121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2308_CR13","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston, S. R. D. et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE). J. Clin. Oncol. 38, 3987\u20133998 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2308_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(89)91141-0","volume":"1","author":"T Fornander","year":"1989","unstructured":"Fornander, T. et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1, 117\u2013120 (1989).","journal-title":"Lancet"},{"key":"2308_CR15","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/jnci\/91.19.1654","volume":"91","author":"L Bernstein","year":"1999","unstructured":"Bernstein, L. et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J. Natl Cancer Inst. 91, 1654\u20131662 (1999).","journal-title":"J. Natl Cancer Inst."},{"key":"2308_CR16","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(00)02677-5","volume":"356","author":"L Bergman","year":"2000","unstructured":"Bergman, L. et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres\u2019 ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356, 881\u2013887 (2000).","journal-title":"Lancet"},{"key":"2308_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","volume":"86","author":"B Fisher","year":"1994","unstructured":"Fisher, B. et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst. 86, 527\u2013537 (1994).","journal-title":"J. Natl Cancer Inst."},{"key":"2308_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/jnci\/dji057","volume":"97","author":"AJ Swerdlow","year":"2005","unstructured":"Swerdlow, A. J., Jones, M. E. & British Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case\u2013control study. J. Natl Cancer Inst. 97, 375\u2013384 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"2308_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick, J. et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 16, 67\u201375 (2015).","journal-title":"Lancet Oncol."},{"key":"2308_CR20","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher, B. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 97, 1652\u20131662 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"2308_CR21","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies, C. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381, 805\u2013816 (2013).","journal-title":"Lancet"},{"key":"2308_CR22","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1126\/science.1068537","volume":"295","author":"Y Shang","year":"2002","unstructured":"Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 295, 2465\u20132468 (2002).","journal-title":"Science"},{"key":"2308_CR23","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1126\/science.7985022","volume":"266","author":"KS Korach","year":"1994","unstructured":"Korach, K. S. Insights from the study of animals lacking functional estrogen receptor. Science 266, 1524\u20131527 (1994).","journal-title":"Science"},{"key":"2308_CR24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1210\/edrv.20.3.0370","volume":"20","author":"JF Couse","year":"1999","unstructured":"Couse, J. F. & Korach, K. S. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 20, 358\u2013417 (1999).","journal-title":"Endocr. Rev."},{"key":"2308_CR25","first-page":"1288","volume":"57","author":"R Davies","year":"1997","unstructured":"Davies, R. et al. Tamoxifen causes gene mutations in the livers of lambda\/lacI transgenic rats. Cancer Res. 57, 1288\u20131293 (1997).","journal-title":"Cancer Res."},{"key":"2308_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/mutage\/gep022","volume":"24","author":"K Brown","year":"2009","unstructured":"Brown, K. Is tamoxifen a genotoxic carcinogen in women? Mutagenesis 24, 391\u2013404 (2009).","journal-title":"Mutagenesis"},{"key":"2308_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/gcc.20781","volume":"49","author":"R Fles","year":"2010","unstructured":"Fles, R. et al. Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. Genes Chromosomes Cancer 49, 699\u2013710 (2010).","journal-title":"Genes Chromosomes Cancer"},{"key":"2308_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-007-9823-1","volume":"112","author":"WE Hoogendoorn","year":"2008","unstructured":"Hoogendoorn, W. E. et al. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res. Treat. 112, 99\u2013108 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"2308_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"DA Levine","year":"2013","unstructured":"Levine, D. A. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67\u201373 (2013).","journal-title":"Nature"},{"key":"2308_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","volume":"31","author":"AD Cherniack","year":"2017","unstructured":"Cherniack, A. D. et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell 31, 411\u2013423 (2017).","journal-title":"Cancer Cell"},{"key":"2308_CR31","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","volume":"171","author":"Cancer Genome Atlas Research Network.","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171, 950\u2013965 (2017).","journal-title":"Cell"},{"key":"2308_CR32","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"AACR Project GENIE Consortium.","year":"2017","unstructured":"AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov. 7, 818\u2013831 (2017).","journal-title":"Cancer Discov."},{"key":"2308_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"2308_CR34","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/ng.3602","volume":"48","author":"WJ Gibson","year":"2016","unstructured":"Gibson, W. J. et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat. Genet. 48, 848\u2013855 (2016).","journal-title":"Nat. Genet."},{"key":"2308_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nbt.3391","volume":"34","author":"MT Chang","year":"2016","unstructured":"Chang, M. T. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34, 155\u2013163 (2016).","journal-title":"Nat. Biotechnol."},{"key":"2308_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).","journal-title":"Genome Biol."},{"key":"2308_CR37","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ccell.2017.04.013","volume":"31","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. A pan-cancer proteogenomic atlas of PI3K\/AKT\/mTOR pathway alterations. Cancer Cell 31, 820\u2013832 (2017).","journal-title":"Cancer Cell"},{"key":"2308_CR38","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/cam4.4434","volume":"11","author":"SG Dashti","year":"2022","unstructured":"Dashti, S. G. et al. Adiposity and breast, endometrial, and colorectal cancer risk in postmenopausal women: quantification of the mediating effects of leptin, C-reactive protein, fasting insulin, and estradiol. Cancer Med. 11, 1145\u20131159 (2022).","journal-title":"Cancer Med."},{"key":"2308_CR39","first-page":"1531","volume":"11","author":"R Kaaks","year":"2002","unstructured":"Kaaks, R., Lukanova, A. & Kurzer, M. S. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomarkers Prev. 11, 1531\u20131543 (2002).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"2308_CR40","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ajog.2011.05.042","volume":"205","author":"RE Schmandt","year":"2011","unstructured":"Schmandt, R. E., Iglesias, D. A., Co, N. N. & Lu, K. H. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am. J. Obstet. Gynecol. 205, 518\u2013525 (2011).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"2308_CR41","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/gme.0b013e3181cec85d","volume":"17","author":"EW Freeman","year":"2010","unstructured":"Freeman, E. W., Sammel, M. D., Lin, H. & Gracia, C. R. Obesity and reproductive hormone levels in the transition to menopause. Menopause 17, 718\u2013726 (2010).","journal-title":"Menopause"},{"key":"2308_CR42","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1200\/JCO.2016.69.4638","volume":"34","author":"MA Onstad","year":"2016","unstructured":"Onstad, M. A., Schmandt, R. E. & Lu, K. H. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J. Clin. Oncol. 34, 4225\u20134230 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2308_CR43","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1056\/NEJM197512042932302","volume":"293","author":"DC Smith","year":"1975","unstructured":"Smith, D. C., Prentice, R., Thompson, D. J. & Herrmann, W. L. Association of exogenous estrogen and endometrial carcinoma. N. Engl. J. Med. 293, 1164\u20131167 (1975).","journal-title":"N. Engl. J. Med."},{"key":"2308_CR44","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1056\/NEJM197512042932303","volume":"293","author":"HK Ziel","year":"1975","unstructured":"Ziel, H. K. & Finkle, W. D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N. Engl. J. Med. 293, 1167\u20131170 (1975).","journal-title":"N. Engl. J. Med."},{"key":"2308_CR45","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.1038\/onc.2008.245","volume":"27","author":"TL Yuan","year":"2008","unstructured":"Yuan, T. L. & Cantley, L. C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497\u20135510 (2008).","journal-title":"Oncogene"},{"key":"2308_CR46","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1158\/2159-8290.CD-11-0039","volume":"1","author":"LW Cheung","year":"2011","unstructured":"Cheung, L. W. et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 1, 170\u2013185 (2011).","journal-title":"Cancer Discov."},{"key":"2308_CR47","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/bjs.10899","volume":"105","author":"CA Fleming","year":"2018","unstructured":"Fleming, C. A. et al. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br. J. Surg. 105, 1098\u20131106 (2018).","journal-title":"Br. J. Surg."},{"key":"2308_CR48","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929\u20131940 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2308_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12672-019-0358-9","volume":"10","author":"AC Rodriguez","year":"2019","unstructured":"Rodriguez, A. C., Blanchard, Z., Maurer, K. A. & Gertz, J. Estrogen signaling in endometrial cancer: a key oncogenic pathway with several open questions. Horm. Cancer 10, 51\u201363 (2019).","journal-title":"Horm. Cancer"},{"key":"2308_CR50","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1073\/pnas.96.6.3287","volume":"96","author":"OO Adesanya","year":"1999","unstructured":"Adesanya, O. O., Zhou, J., Samathanam, C., Powell-Braxton, L. & Bondy, C. A. Insulin-like growth factor 1 is required for G2 progression in the estradiol-induced mitotic cycle. Proc. Natl Acad. Sci. USA 96, 3287\u20133291 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2308_CR51","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1210\/endo.141.9.7649","volume":"141","author":"DM Klotz","year":"2000","unstructured":"Klotz, D. M., Hewitt, S. C., Korach, K. S. & Diaugustine, R. P. Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-\u03b1. Endocrinology 141, 3430\u20133439 (2000).","journal-title":"Endocrinology"},{"key":"2308_CR52","first-page":"743","volume":"7","author":"SM Aronica","year":"1993","unstructured":"Aronica, S. M. & Katzenellenbogen, B. S. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol. Endocrinol. 7, 743\u2013752 (1993).","journal-title":"Mol. Endocrinol."},{"key":"2308_CR53","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1210\/endo.141.12.7836","volume":"141","author":"MB Martin","year":"2000","unstructured":"Martin, M. B. et al. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141, 4503\u20134511 (2000).","journal-title":"Endocrinology"},{"key":"2308_CR54","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1677\/ERC-08-0117","volume":"16","author":"H Kashima","year":"2009","unstructured":"Kashima, H. et al. Autocrine stimulation of IGF1 in estrogen-induced growth of endometrial carcinoma cells: involvement of the mitogen-activated protein kinase pathway followed by up-regulation of cyclin D1 and cyclin E. Endocr. Relat. Cancer 16, 113\u2013122 (2009).","journal-title":"Endocr. Relat. Cancer"},{"key":"2308_CR55","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.1073\/pnas.94.12.6535","volume":"94","author":"PS Cooke","year":"1997","unstructured":"Cooke, P. S. et al. Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc. Natl Acad. Sci. USA 94, 6535\u20136540 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2308_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/mp.54.3.145","volume":"54","author":"RC Baxter","year":"2001","unstructured":"Baxter, R. C. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol. Pathol. 54, 145\u2013148 (2001).","journal-title":"Mol. Pathol."},{"key":"2308_CR57","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.cell.2021.03.009","volume":"184","author":"SC Dentro","year":"2021","unstructured":"Dentro, S. C. et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell 184, 2239\u20132254 (2021).","journal-title":"Cell"},{"key":"2308_CR58","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s43018-023-00533-y","volume":"4","author":"I Leshchiner","year":"2023","unstructured":"Leshchiner, I. et al. Inferring early genetic progression in cancers with unobtainable premalignant disease. Nat. Cancer 4, 550\u2013563 (2023).","journal-title":"Nat. Cancer"},{"key":"2308_CR59","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S0140-6736(94)92692-1","volume":"343","author":"FE van Leeuwen","year":"1994","unstructured":"van Leeuwen, F. E. et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343, 448\u2013452 (1994).","journal-title":"Lancet"},{"key":"2308_CR60","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.18632\/oncotarget.2675","volume":"6","author":"A Berg","year":"2015","unstructured":"Berg, A. et al. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget 6, 1327\u20131339 (2015).","journal-title":"Oncotarget"},{"key":"2308_CR61","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41586-020-2214-z","volume":"580","author":"L Moore","year":"2020","unstructured":"Moore, L. et al. The mutational landscape of normal human endometrial epithelium. Nature 580, 640\u2013646 (2020).","journal-title":"Nature"},{"key":"2308_CR62","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/path.5314","volume":"249","author":"V Lac","year":"2019","unstructured":"Lac, V. et al. Oncogenic mutations in histologically normal endometrium: the new normal? J. Pathol. 249, 173\u2013181 (2019).","journal-title":"J. Pathol."},{"key":"2308_CR63","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1614814","volume":"376","author":"MS Anglesio","year":"2017","unstructured":"Anglesio, M. S. et al. Cancer-associated mutations in endometriosis without cancer. N. Engl. J. Med. 376, 1835\u20131848 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2308_CR64","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.fertnstert.2022.05.030","volume":"118","author":"TH Praetorius","year":"2022","unstructured":"Praetorius, T. H. et al. Molecular analysis suggests oligoclonality and metastasis of endometriosis lesions across anatomically defined subtypes. Fertil. Steril. 118, 524\u2013534 (2022).","journal-title":"Fertil. Steril."},{"key":"2308_CR65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/path.5566","volume":"253","author":"L Li","year":"2021","unstructured":"Li, L. et al. Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma. J. Pathol. 253, 119\u2013128 (2021).","journal-title":"J. Pathol."},{"key":"2308_CR66","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41588-024-01703-z","volume":"56","author":"Z Hu","year":"2024","unstructured":"Hu, Z. et al. Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response. Nat. Genet. 56, 637\u2013651 (2024).","journal-title":"Nat. Genet."},{"key":"2308_CR67","doi-asserted-by":"crossref","unstructured":"Yizhak, K. et al. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science 364, eaaw0726 (2019).","DOI":"10.1126\/science.aaw0726"},{"key":"2308_CR68","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/09513590.2017.1409714","volume":"34","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. et al. Metformin is associated with reduced cell proliferation in human endometrial cancer by inhibiting PI3K\/AKT\/mTOR signaling. Gynecol. Endocrinol. 34, 428\u2013432 (2018).","journal-title":"Gynecol. Endocrinol."},{"key":"2308_CR69","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/cen.13830","volume":"89","author":"SR Davis","year":"2018","unstructured":"Davis, S. R. et al. The benefits of adding metformin to tamoxifen to protect the endometrium\u2014a randomized placebo-controlled trial. Clin. Endocrinol. 89, 605\u2013612 (2018).","journal-title":"Clin. Endocrinol."},{"key":"2308_CR70","doi-asserted-by":"publisher","first-page":"e87062","DOI":"10.1172\/jci.insight.87062","volume":"1","author":"LM Sholl","year":"2016","unstructured":"Sholl, L. M. et al. Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight 1, e87062 (2016).","journal-title":"JCI Insight"},{"key":"2308_CR71","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/S0090-8258(22)01398-1","volume":"166","author":"E Evans","year":"2022","unstructured":"Evans, E. et al. Whole exome sequencing provides loss of heterozygosity (LoH) data comparable to that of whole genome sequencing (171). Gynecol. Oncol. 166, S100 (2022).","journal-title":"Gynecol. Oncol."},{"key":"2308_CR72","doi-asserted-by":"publisher","first-page":"e2300152","DOI":"10.1200\/PO.23.00152","volume":"7","author":"I Ogobuiro","year":"2023","unstructured":"Ogobuiro, I. et al. Multiomic characterization reveals a distinct molecular landscape in young-onset pancreatic cancer. JCO Precis. Oncol. 7, e2300152 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"2308_CR73","doi-asserted-by":"crossref","unstructured":"Muquith, M. et al. Tissue-specific thresholds of mutation burden associated with anti-PD-1\/L1 therapy benefit and prognosis in microsatellite-stable cancers. Nat. Cancer 5, 1121\u20131129 (2024).","DOI":"10.1038\/s43018-024-00752-x"},{"key":"2308_CR74","unstructured":"Auwera, Van der, G. A & O\u2019Connor, B. D. Genomics in the Cloud: Using Docker, GATK, and WDL in Terra (O\u2019Reilly Media, 2020)."},{"key":"2308_CR75","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1093\/bioinformatics\/btr446","volume":"27","author":"K Cibulskis","year":"2011","unstructured":"Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601\u20132602 (2011).","journal-title":"Bioinformatics"},{"key":"2308_CR76","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"2308_CR77","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor\u2013normal sample pairs. Bioinformatics 28, 1811\u20131817 (2012).","journal-title":"Bioinformatics"},{"key":"2308_CR78","doi-asserted-by":"publisher","first-page":"E2423","DOI":"10.1002\/humu.22771","volume":"36","author":"AH Ramos","year":"2015","unstructured":"Ramos, A. H. et al. Oncotator: cancer variant annotation tool. Hum. Mutat. 36, E2423\u2013E2429 (2015).","journal-title":"Hum. Mutat."},{"key":"2308_CR79","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1093\/nar\/gks1443","volume":"41","author":"M Costello","year":"2013","unstructured":"Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013).","journal-title":"Nucleic Acids Res."},{"key":"2308_CR80","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.celrep.2016.10.009","volume":"17","author":"M Giannakis","year":"2016","unstructured":"Giannakis, M. et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 17, 1206 (2016).","journal-title":"Cell Rep."},{"key":"2308_CR81","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cels.2018.03.002","volume":"6","author":"K Ellrott","year":"2018","unstructured":"Ellrott, K. et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 6, 271\u2013281 (2018).","journal-title":"Cell Syst."},{"key":"2308_CR82","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41592-018-0036-9","volume":"15","author":"A Taylor-Weiner","year":"2018","unstructured":"Taylor-Weiner, A. et al. DeTiN: overcoming tumor-in-normal contamination. Nat. Methods 15, 531\u2013534 (2018).","journal-title":"Nat. Methods"},{"key":"2308_CR83","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/ng.3343","volume":"47","author":"MD Stachler","year":"2015","unstructured":"Stachler, M. D. et al. Paired exome analysis of Barrett\u2019s esophagus and adenocarcinoma. Nat. Genet. 47, 1047\u20131055 (2015).","journal-title":"Nat. Genet."},{"key":"2308_CR84","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/bib\/bbs017","volume":"14","author":"H Thorvaldsdottir","year":"2013","unstructured":"Thorvaldsdottir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178\u2013192 (2013).","journal-title":"Brief. Bioinform."},{"key":"2308_CR85","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495\u2013501 (2014).","journal-title":"Nature"},{"key":"2308_CR86","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B."},{"key":"2308_CR87","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ccell.2018.06.013","volume":"34","author":"RK Gopal","year":"2018","unstructured":"Gopal, R. K. et al. Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in H\u00fcrthle cell carcinoma. Cancer Cell 34, 242\u2013255 (2018).","journal-title":"Cancer Cell"},{"key":"2308_CR88","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41568-018-0060-1","volume":"18","author":"Z Sondka","year":"2018","unstructured":"Sondka, Z. et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat. Rev. Cancer 18, 696\u2013705 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"2308_CR89","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413\u2013421 (2012).","journal-title":"Nat. Biotechnol."},{"key":"2308_CR90","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-20-0790","volume":"11","author":"J Chung","year":"2021","unstructured":"Chung, J. et al. DNA polymerase and mismatch repair exert distinct microsatellite instability signatures in normal and malignant human cells. Cancer Discov. 11, 1176\u20131191 (2021).","journal-title":"Cancer Discov."},{"key":"2308_CR91","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ng.3557","volume":"48","author":"J Kim","year":"2016","unstructured":"Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600\u2013606 (2016).","journal-title":"Nat. Genet."},{"key":"2308_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1836-7","volume":"20","author":"A Taylor-Weiner","year":"2019","unstructured":"Taylor-Weiner, A. et al. Scaling computational genomics to millions of individuals with GPUs. Genome Biol. 20, 228 (2019).","journal-title":"Genome Biol."},{"key":"2308_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04002-4","volume":"9","author":"NJ Haradhvala","year":"2018","unstructured":"Haradhvala, N. J. et al. Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair. Nat. Commun. 9, 1746 (2018).","journal-title":"Nat. Commun."},{"key":"2308_CR94","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cell.2020.01.026","volume":"180","author":"Y Dou","year":"2020","unstructured":"Dou, Y. et al. Proteogenomic characterization of endometrial carcinoma. Cell 180, 729\u2013748 (2020).","journal-title":"Cell"},{"key":"2308_CR95","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","volume":"33","author":"AM Taylor","year":"2018","unstructured":"Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676\u2013689 (2018).","journal-title":"Cancer Cell"},{"key":"2308_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0075-5","volume":"4","author":"Y Kuang","year":"2018","unstructured":"Kuang, Y. et al. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer 4, 22 (2018).","journal-title":"NPJ Breast Cancer"},{"key":"2308_CR97","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ng.3391","volume":"47","author":"M Janiszewska","year":"2015","unstructured":"Janiszewska, M. et al. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat. Genet. 47, 1212\u20131219 (2015).","journal-title":"Nat. Genet."},{"key":"2308_CR98","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/bimj.201300048","volume":"56","author":"SH Jung","year":"2014","unstructured":"Jung, S. H. Stratified Fisher\u2019s exact test and its sample size calculation. Biom. J. 56, 129\u2013140 (2014).","journal-title":"Biom. J."},{"key":"2308_CR99","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/bimj.201500032","volume":"57","author":"A Mart\u00edn-Andr\u00e9s","year":"2015","unstructured":"Mart\u00edn-Andr\u00e9s, A. & Herranz-Tejedor, I. Regarding Paper \u2018Stratified Fisher\u2019s exact test and its sample size calculation\u2019. Biom. J. 57, 930 (2015).","journal-title":"Biom. J."},{"key":"2308_CR100","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/nature04225","volume":"438","author":"H Wu","year":"2005","unstructured":"Wu, H. et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438, 981\u2013987 (2005).","journal-title":"Nature"},{"key":"2308_CR101","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"2308_CR102","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90\u2013W97 (2016).","journal-title":"Nucleic Acids Res."},{"key":"2308_CR103","doi-asserted-by":"publisher","first-page":"D674","DOI":"10.1093\/nar\/gkn653","volume":"37","author":"CF Schaefer","year":"2009","unstructured":"Schaefer, C. F. et al. PID: the Pathway Interaction Database. Nucleic Acids Res. 37, D674\u2013D679 (2009).","journal-title":"Nucleic Acids Res."},{"key":"2308_CR104","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00280-014-2605-7","volume":"74","author":"JM Reid","year":"2014","unstructured":"Reid, J. M. et al. Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies. Cancer Chemother. Pharmacol. 74, 1271\u20131278 (2014).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2308_CR105","doi-asserted-by":"publisher","unstructured":"De Clercq, K., Hennes, A. & Vriens, J. Isolation of mouse endometrial epithelial and stromal cells for in vitro decidualization. J. Vis. Exp. https:\/\/doi.org\/10.3791\/55168 (2017).","DOI":"10.3791\/55168"},{"key":"2308_CR106","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12859-018-2139-9","volume":"19","author":"M Cornwell","year":"2018","unstructured":"Cornwell, M. et al. VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis. BMC Bioinformatics 19, 135 (2018).","journal-title":"BMC Bioinformatics"},{"key":"2308_CR107","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell, C. et al. Transcript assembly and quantification by RNA-seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511\u2013515 (2010).","journal-title":"Nat. Biotechnol."},{"key":"2308_CR108","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1093\/bioinformatics\/bts356","volume":"28","author":"L Wang","year":"2012","unstructured":"Wang, L., Wang, S. & Li, W. RSeQC: quality control of RNA-seq experiments. Bioinformatics 28, 2184\u20132185 (2012).","journal-title":"Bioinformatics"},{"key":"2308_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02308-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02308-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02308-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:01:45Z","timestamp":1757602905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-025-02308-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":109,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2308"],"URL":"https:\/\/doi.org\/10.1038\/s41588-025-02308-w","relation":{},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"17 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.G. receives research funds from IBM, Pharmacyclics\u2013AbbVie, Bayer, Genentech, Calico, Ultima Genomics, Inocras, Google, Kite and Novartis and is also an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSEye and MinimuMM-seq, and DLBclass. He is a founder of and a consultant to and holds privately held equity in Scorpion Therapeutics; he is also a founder of and holds privately held equity in PreDICTA Biosciences; and he holds privately held equity in Antares Therapeutics. R.J. received research funding from Lilly, Pfizer and Novartis and serves on an advisory board for GE Healthcare and Carrick Therapeutics. Y.E.M. is a consultant in Foresee Genomics. C.P.P. holds stock and other ownership interests in Xsphera Biosciences and receives honoraria from Bio-Rad and consults or advises for DropWorks and Xsphera Biosciences. C.P.P. also has sponsored research agreements with Daiichi Sankyo, Bicycle Therapeutics, Transcenta, Bicara Therapeutics, AstraZeneca, Intellia Therapeutics, Janssen Pharmaceuticals and Array BioPharma. W.J.G. is a cofounder of and holds equity in Ampressa Therapeutics, is a consultant for and holds equity in inference and has received consulting fees from Boston Clinical Research Institute, Belharra Therapeutics, Faze Medicine and ImmPACT Bio. E.M.V.A. reports an advisory role and\/or consulting with Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio and Monte Rosa; research support from Novartis and BMS; equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft and Monte Rosa; travel reimbursement from Roche\u2013Genentech and institutional patents filed on chromatin mutations and immunotherapy response and methods for clinical interpretation. W.Z. receives research funding and advises for Astellas Pharma. U.A.M. reports receiving consulting fees received from Merck, Novartis, Blueprint Medicines, AstraZeneca and NextCure as well as participating on a data safety monitoring board or an advisory board for Symphogen and Advaxis. M.J.E.M. receives research funding from W.J. Thijn Stichting. I.L. is a consultant for PACT Pharma and is a board member, scientific advisor and consultant to Ennov1. A.N. is currently employed by AstraZeneca. J.G. and M.R. disclose a financial association with Caris Life Sciences, including full-time employment, travel and\/or speaking expenses and stock and\/or stock options. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}